Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OKYO vs DRMA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OKYO Captures Overall Composite Edge (42.8 HOLD vs 42.2 HOLD), While DRMA Leads 3–0 on Growth & Valuation Pillars

OKYO Overall Winner 6-Pillar Tally: OKYO 0 – 3 DRMA (3 Tie) Matrix Metrics: OKYO 5 – 1 DRMA

As of Nov 20, 2026, OKYO Pharma Limited (OKYO) captures the overall head-to-head institutional edge over Dermata Therapeutics, Inc. (DRMA) on higher Unified Composite conviction (42.8/100 HOLD vs. 42.2/100 HOLD) after splitting the core matrix 5–1 (led by composite factor balance), while DRMA wins 3–0 across the 6-pillar growth and valuation breakdown. OKYO trades at $1.07 (N/M Forward P/E, 0.0% operating margin) versus DRMA at $0.51 (N/M Forward P/E, -13082.3% operating margin).

  • Growth vs. Quality Trade-Off: OKYO earns the overall head-to-head edge with a stronger Unified Composite Score (42.8/100 HOLD vs. DRMA 42.2/100 HOLD) and 1.05β · 76% Vol risk profile, whereas DRMA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: OKYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8); meanwhile DRMA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OKYO vs DRMA
OKYO NASDAQ Head-to-Head Winner
OKYO Pharma Limited Ordinary Shares
Biological Products, (No Diagnostic Substances)
$1.07
-7.76% 1D
Market Cap $62.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 76% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 50.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 32
RSI-14: 31.8 · SMA20: $1.35 · SMA50: $1.38
DRMA NASDAQ
Dermata Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.51
-4.23% 1D
Market Cap $2.6M
TTM Revenue $74,137
Forward P/E N/M
Beta / 30D Vol 1.09β · 105% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 35.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.9%), weak momentum, RSI 27
RSI-14: 27.4 · SMA20: $0.71 · SMA50: $0.90

6-Pillar Scorecard Institutional Category Breakdown (OKYO 0 – 3 DRMA)

Columns: Metric · OKYO · DRMA
1. Valuation Multiples DRMA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 35.4x
2. Growth & Scale Tie
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $74,137
Market Cap $62.7M $2.6M
3. Profitability & Quality DRMA
Gross Margin N/A 54.1%
Operating Margin 0.0% -13082.3%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -263.8% -241.5%
4. Balance Sheet & Cash Flow DRMA
Cash Generation (TTM) N/A -$7.9M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.23 Book/Sh · -263.8% ROE $0.79 Book/Sh · -241.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OKYO (5) vs DRMA (1)
Institutional Metric OKYO DRMA Criterion Row Edge
Market Capitalization
Scale
$62.7M $2.6M Larger Scale OKYO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% -13082.3% Higher Margin OKYO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-263.8% -241.5% Higher ROE DRMA
52-Week Range Position
Momentum
3% ($1–$3) 0% ($0–$5) Stronger Trend OKYO
Beta / 30D Volatility
Risk Regime
1.05β · 76% Vol 1.09β · 105% Vol Lower Realized Risk OKYO
Unified Institutional Score
Composite Signal
42.8 / 100 (HOLD) 42.2 / 100 (HOLD) Higher Composite OKYO
Trailing 12M Revenue (USD)
Operating Scale
N/A $74,137 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 54.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 35.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($0.23 Book/Sh · -263.8% ROE) -$7.9M EBITDA ($0.79 Book/Sh · -241.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OKYO +13.82 pp
OKYO: -27.21% · DRMA: -41.03%
3M Horizon OKYO +40.07 pp
OKYO: -28.67% · DRMA: -68.74%
6M Horizon OKYO +25.2 pp
OKYO: -34.36% · DRMA: -59.56%
1Y Horizon OKYO +32.09 pp
OKYO: -47.03% · DRMA: -79.12%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKYO vs DRMA. Trailing 12-month operating profitability (OKYO 0.0% vs DRMA -13082.3%) and valuation multiples (OKYO N/M vs DRMA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

OKYO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-263.8% · N/M
DRMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$74,137
Gross Margin54.1%
Op. Margin-13082.3%
ROE / Fwd P/E-241.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OKYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OKYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DRMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DRMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OKYO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DRMA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.6M market capitalization and -13082.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OKYO vs DRMA Key Questions & Quantitative Answers

As of Nov 20, 2026, OKYO Pharma Limited (OKYO) captures the overall head-to-head institutional edge over Dermata Therapeutics, Inc. (DRMA) on higher Unified Composite conviction (42.8/100 HOLD vs. 42.2/100 HOLD) after splitting the core matrix 5–1 (led by composite factor balance), while DRMA wins 3–0 across the 6-pillar growth and valuation breakdown. OKYO trades at $1.07 (N/M Forward P/E, 0.0% operating margin) versus DRMA at $0.51 (N/M Forward P/E, -13082.3% operating margin). Growth vs. Quality Trade-Off: OKYO earns the overall head-to-head edge with a stronger Unified Composite Score (42.8/100 HOLD vs. DRMA 42.2/100 HOLD) and 1.05β · 76% Vol risk profile, whereas DRMA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OKYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8); meanwhile DRMA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OKYO and DRMA split Growth & Scale metrics: OKYO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DRMA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $74,137 TTM revenue (54.1% gross margin, -13082.3% operating margin). On trailing 12-month operating scale, OKYO generates N/A in USD-normalized revenue versus $74,137 for DRMA. In operating R&D and SG&A reinvestment, OKYO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DRMA.

DRMA screens cheaper on headline valuation multiples. OKYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas DRMA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 35.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OKYO (-263.8% ROE) versus DRMA (-241.5% ROE) capital efficiency.

In options market volatility and institutional positioning, OKYO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 76% Vol realized risk). By comparison, DRMA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 105% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.